Updated:
Mirna Therapeutics
Mirna Therapeutics is an opaque firm headquartered in Shanghai with offices globally; no public records disclose principals, AUM, or investment activity.
Mirna Therapeutics
Mirna Therapeutics maintains a global footprint with offices in Shanghai, Cambridge (UK), Menlo Park, New York, Seattle, Austin, and San Diego, as listed on its website (mirnarx.com). No founding year, named principals, or wealth origin are disclosed in public sources. The firm's name and website imply a focus on therapeutics, likely in the biotechnology or pharmaceutical space, but no specific asset-class mix, stage coverage, or investment structure — such as direct deals, fund commitments, or co-investments — is publicly documented. No portfolio companies or deals are attributable in any public record. The total number of professionals remains undisclosed. No adjacent vehicles, philanthropic foundations, or operational arms are identifiable. There is no verifiable recent activity within the last 24 months. The firm's structural differentiator is its complete lack of public disclosure — it offers no insight into governance, succession, or operating-company relationships, making it a highly opaque entity in the family-office or investment-manager universe.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Shanghai, China
Additional offices
Cambridge, United Kingdom · Menlo Park, United States · New York, United States · Seattle, United States · Austin, United States · San Diego, United States
Frequently asked questions
What is Mirna Therapeutics?
Mirna Therapeutics is a firm operating from Shanghai with additional offices in Cambridge (UK), Menlo Park, New York, Seattle, Austin, and San Diego. Its website (mirnarx.com) suggests a focus on therapeutics, but no founding year, named principals, or investment strategy is publicly documented. The firm does not disclose AUM, deployment, or portfolio companies in any public record.
Who runs investment decisions at Mirna Therapeutics?
No named principals or investment decision-makers are publicly traceable for Mirna Therapeutics. The firm's leadership team is not disclosed on its website or in any public source. This absence of disclosure limits external due diligence.
Is Mirna Therapeutics structured as a single family office, multi-family office, or asset manager?
Mirna Therapeutics does not publicly specify its firm type or structure. Based on its name and website, it may operate as a therapeutics-focused investment or operating entity, but no classification — such as single-family office, multi-family office, or asset manager — is confirmed in public records.
What investment stages or sectors does Mirna Therapeutics target?
Mirna Therapeutics does not disclose its target investment stages, sectors, or asset classes in any public source. The firm's name suggests a focus on therapeutics, but no sector tags, stage preferences, or geographic focus beyond its office locations are verifiable.
What is the wealth origin behind Mirna Therapeutics?
The wealth origin of Mirna Therapeutics is not publicly disclosed. No family, principal, or institutional source of capital is attributable in any public record. The firm remains opaque regarding its funding base.
Does Mirna Therapeutics participate in fund commitments or direct deals?
Mirna Therapeutics does not publicly disclose its investment structure, including whether it commits to funds, engages in direct deals, or co-invests alongside external GPs. No associated portfolio companies or deals are documented in public sources.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: